<?xml version="1.0" encoding="UTF-8"?>
<p id="p0485">Furthermore, evidences suggest that imatinib can modulate the immune response by sundry mechanisms,
 <xref rid="b1115" ref-type="bibr">223</xref>, 
 <xref rid="b1120" ref-type="bibr">224</xref>, 
 <xref rid="b1125" ref-type="bibr">225</xref> for several diseases, such as rheumatoid arthritis,
 <xref rid="b1130" ref-type="bibr">
  <sup>226</sup>
 </xref> asthma,
 <xref rid="b1135" ref-type="bibr">
  <sup>227</sup>
 </xref> and Crohn's disease.
 <xref rid="b1140" ref-type="bibr">
  <sup>228</sup>
 </xref> This information insinuates that such drug might perform its potentially beneficial immunomodulatory role as a treatment alternative for COVID-19 pneumonia. In addition, the use of imatinib as treatment appears to be reasonable from an economic point of view and its high availability in hospitals,
 <xref rid="b1145" ref-type="bibr">
  <sup>229</sup>
 </xref> since this drug is well tolerated and the risk of severe adverse effects is relatively low, especially in short-term administration.
 <xref rid="b1150" ref-type="bibr">
  <sup>230</sup>
 </xref> It is also recognized that adverse effects, mostly mild to moderate in intensity, will be easily controlled by dose reduction or discontinuation.
 <xref rid="b1155" ref-type="bibr">
  <sup>231</sup>
 </xref>
</p>
